Helsinn And BridgeBio Ink Infigratinib Cancer Pact

Duo Will Co-develop And Commercialise FGFR1-3 inhibitor In Oncology

 
• By Sten Stovall
  
Helsinn Handshake
BridgeBio retains full rights to infigratinib for use in skeletal dysplasias • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business